Reagents and instruments for immunology, cell biology and molecular biology.
 
> Ferrostatin-1 [347174-05-4]

Ferrostatin-1 [347174-05-4]

Print Print
Please log in

Cat# HY-100579-1ml

Size : 10mM/1mL

Brand : MedChemExpress

Request more information

Contact local distributor :


Phone : +1 850 650 7790

Ferrostatin-1 (Fer-1), a potent and selective ferroptosis inhibitor, suppresses Erastin-induced ferroptosis in HT-1080 cells (EC50=60 nM). Ferrostatin-1, a synthetic antioxidant, acts via a reductive mechanism to prevent damage to membrane lipids and thereby inhibits cell death. Ferrostatin-1 exhibits antifungal activity.

For research use only. We do not sell to patients.

Ferrostatin-1 Chemical Structure

Ferrostatin-1 Chemical Structure

CAS No. : 347174-05-4

This product is a controlled substance and not for sale in your territory.

Based on 754 publication(s) in Google Scholar

Other Forms of Ferrostatin-1:

  • Ferrostatin-1 diyne Get quote

    Ferrostatin-1 purchased from MedChemExpress. Usage Cited in: J Funct Foods. 2023 May.

    Ferrostatin-1 (Fer-1) significantly restores the decreased cell viability in HK-1 and 5-8F cells induced by α-solanine.

    Ferrostatin-1 purchased from MedChemExpress. Usage Cited in: Sleep Breath. 2023 Mar 1.  [Abstract]

    The protein content of GPX4 and FTH1 is signifcantly upregulated in intermittent hypoxia (IH)+ferrostatin-1 (5 μM) group, in rat liver (BRL‑3A) cells.

    Ferrostatin-1 purchased from MedChemExpress. Usage Cited in: Cell Discov. 2022 May 3;8(1):40.  [Abstract]

    U2OS cells are incubated with DMSO or OSMI-1 for 12 h and then pre-treated with Ferrostatin-1 (Fer-1; 2 μM) for 2 h before the treatment of RSL3 for 4 h. Cells are stained with PI and cell death is then assessed by flow cytometry.

    Ferrostatin-1 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2022 Oct;56:102435.  [Abstract]

    Primary HSCs and LX-2 cells are treated with EA (LX-2 cells: 40 μM; primary HSCs: 45 μM), Ferrostatin-1 (1 μM) and ZVAD-FMK (10 μM), and cells are stained with PI (red fluorescence) to examine the dead cells.

    Ferrostatin-1 purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2022 Feb;76:103847.  [Abstract]

    Mitochondrial membrane potential (ΔΨm) measured by fluorescence microscopy of MCC treated with TBHP and rescued via Ferrostatin-1 (Fer-1; 1 μM) using JC-1 Mitochondrial Membrane Potential Assay. In Fer-1 and DFO group, red fluorescence (poly JC-1) is increased and green fluorescence (mono JC-1) is decreased.

    Ferrostatin-1 purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2021 Nov 19;13:23-36.  [Abstract]

    H1299 and H460 cells are treated with Curcumenol with or without Ferrostatin-1 (Fer-1; 1 μM) for 24 h, and the cell viability is analyzed.

    Ferrostatin-1 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2021 Jun 23;40(1):206.  [Abstract]

    T47D cells are treated with Metformin (5 mM) for 48 h in the absence or presence of Ferrostatin-1 (1 μM) for 48 h.

    Ferrostatin-1 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2021 Jul 10;510:93-104.  [Abstract]

    Ferrostatin-1(2 μM) has the ability to fully restore the cell viability impaired by Erastin (5 μM) treated control cells in GBC-SD cells.

    Ferrostatin-1 purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2021 Mar 1;17(4):942-956.  [Abstract]

    After the gallic acid treatment, Fe2+, ROS, and MDA are significantly increased compared to the control group, and at the same time, the content of GSH is significantly reduced. The intervention of Ferrostatin-1 (2 μM) while treating the cells with gallic acid reversed the changes in these indicators to varying degrees.

    Ferrostatin-1 purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2021 Mar 1;17(4):942-956.  [Abstract]

    Gallic acid affects the expression of ferroptosis-related proteins. The relative expression levels of GPX4, SLC7A11, and SIGMAR1 decreased, while the relative expression levels of ATF4 and TFR1 increased. Ferrostatin-1 (2 μM) as a ferroptosis inhibitor reverses the expression trend of these proteins.

    Ferrostatin-1 purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2020 May 8;5(1):51.  [Abstract]

    Erastin-induced cell death in lung cancer cells is almost blocked by cotreatment with the Ferrostatin-1 (Fer-1; 24 h) in H460 and H1299 cells.

    Ferrostatin-1 purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Aug 2;10(21):9865-9887.  [Abstract]

    p53 expression of HepG2 cells after treated with Fer-1 at a concentration of 0-40 nM. The addition of Fer-1 could repress the expression of p53 protein by inhibiting the ferroptosis of SFB formulation.

    Ferrostatin-1 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2020 Sep 15;11(9):756.  [Abstract]

    Acot1 protein levels in different concentrations of DOX-treated HL-1 cell with or without Fer-1 (10 μM) for 24 h. Acot1 expression is decreased at a higher concentration of DOX, while Fer-1 co-treatment partially suppressed this trend.
    Description

    Ferrostatin-1 (Fer-1), a potent and selective ferroptosis inhibitor, suppresses Erastin-induced ferroptosis in HT-1080 cells (EC50=60 nM). Ferrostatin-1, a synthetic antioxidant, acts via a reductive mechanism to prevent damage to membrane lipids and thereby inhibits cell death. Ferrostatin-1 exhibits antifungal activity[1][2][3].

    IC50 & Target

    EC50: 60 nM (Ferroptosis)[1]
    Cellular Effect
    Cell Line Type Value Description References
    Fibroblast EC50
    33 nM
    Compound: Fer-1
    Inhibition of erastin-induced cell death in FRDA patient-derived fibroblast assessed as depletion of cellular ATP incubated for 12 hrs followed by erastin stimulation and measured after by luciferase-linked ATPase enzymatic assay
    Inhibition of erastin-induced cell death in FRDA patient-derived fibroblast assessed as depletion of cellular ATP incubated for 12 hrs followed by erastin stimulation and measured after by luciferase-linked ATPase enzymatic assay
    		[PMID: 33214825]
    HT-1080 EC50
    0.07 μM
    Compound: Fer-1
    Anti-ferroptotic activity against Erastin-induced ferroptosis in human HT-1080 cells assessed as cell activity measured after 24 hrs by Cell Titer-Glo luminescent assay
    Anti-ferroptotic activity against Erastin-induced ferroptosis in human HT-1080 cells assessed as cell activity measured after 24 hrs by Cell Titer-Glo luminescent assay
    		[PMID: 35300093]
    HT-1080 EC50
    0.088 μM
    Compound: Fer-1
    Inhibition of erastin-induced ferroptosis in human HT-1080 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Inhibition of erastin-induced ferroptosis in human HT-1080 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33065375]
    HT-1080 IC50
    95 nM
    Compound: 1; fer-1
    Antiferroptotic activity in human HT1080 cells assessed as inhibition of erastin-induced cell death by Alamar blue assay
    Antiferroptotic activity in human HT1080 cells assessed as inhibition of erastin-induced cell death by Alamar blue assay
    		[PMID: 26696014]
    HT-22 EC50
    81.2 nM
    Compound: Fer-1
    Anti-ferroptotic activity against RSL3-induced ferroptosis in human HT-22 cells assessed as cell viability measured after 24 hrs by MTT assay
    Anti-ferroptotic activity against RSL3-induced ferroptosis in human HT-22 cells assessed as cell viability measured after 24 hrs by MTT assay
    		[PMID: 35796002]
    IMR-32 IC50
    18 nM
    Compound: 1; fer-1
    Antiferroptotic activity in human IMR32 neuroblastoma cells assessed as inhibition of erastin-induced cell death preincubated for 1 hr before erastin stimulation and measured after 13 hrs by fluorescence plate reader method
    Antiferroptotic activity in human IMR32 neuroblastoma cells assessed as inhibition of erastin-induced cell death preincubated for 1 hr before erastin stimulation and measured after 13 hrs by fluorescence plate reader method
    		[PMID: 26696014]
    IMR-32 IC50
    33 nM
    Compound: 1; Fer-1
    Inhibition of erastin-induced ferroptosis in human IMR32 cells preincubated for 1 hr followed by erastin stimulation and measured after 13 hrs by sytox green-based fluorescence assay
    Inhibition of erastin-induced ferroptosis in human IMR32 cells preincubated for 1 hr followed by erastin stimulation and measured after 13 hrs by sytox green-based fluorescence assay
    		[PMID: 30354101]
    LLC-MK2 IC50
    > 240 μM
    Compound: AA1
    Cytotoxicity against monkey LLC-MK2 cells after 96 hrs by Alamar Blue assay
    Cytotoxicity against monkey LLC-MK2 cells after 96 hrs by Alamar Blue assay
    		[PMID: 26410073]
    Lymphocyte EC50
    48 nM
    Compound: Fer-1
    Anti-ferroptotic activity in FRDA patient-derived Lymphocyte assessed as reduction in RSL3-induced lipid peroxidation incubated for overnight followed by RSL3 stimulation and measured after 90 mins by FACS analysis
    Anti-ferroptotic activity in FRDA patient-derived Lymphocyte assessed as reduction in RSL3-induced lipid peroxidation incubated for overnight followed by RSL3 stimulation and measured after 90 mins by FACS analysis
    		[PMID: 33214825]
    NIH3T3 IC50
    0.22 μM
    Compound: Fer-1
    Inhibition of TBHP-induced ferroptosis in mouse NIH/3T3 cells after 12 hrs by WST-8 assay
    Inhibition of TBHP-induced ferroptosis in mouse NIH/3T3 cells after 12 hrs by WST-8 assay
    		[PMID: 31531196]
    NIH3T3 IC50
    0.27 μM
    Compound: Fer-1
    Inhibition of erastin-induced ferroptosis in mouse NIH/3T3 cells after 24 hrs by WST-8 assay
    Inhibition of erastin-induced ferroptosis in mouse NIH/3T3 cells after 24 hrs by WST-8 assay
    		[PMID: 31531196]
    RAW264.7 EC50
    0.04 μM
    Compound: Fer-1
    Anti-ferroptotic activity against RSL-3 induced ferroptosis in mouse RAW264.7 cells assessed as cell activity measured after 24 hrs by Cell Titer-Glo luminescent assay
    Anti-ferroptotic activity against RSL-3 induced ferroptosis in mouse RAW264.7 cells assessed as cell activity measured after 24 hrs by Cell Titer-Glo luminescent assay
    		[PMID: 35300093]
    In Vitro

    Ferrostatin-1 prevents erastin-induced accumulation of cytosolic and lipid ROS. Ferrostatin-1 prevents glutamate-induced neurotoxicity in organotypic rat brain slices[1].
    Ferrostatin-1 (2 μM; 24 h) prevents Glutamate (5 mM)-induced neurotoxicity in a rat organotypic hippocampal slice culture (OHSC)[2].
    Ferrostatin-1 inhibits lipid peroxidation, but not mitochondrial reactive oxygen species formation or lysosomal membrane permeability[2].
    Ferrostatin-1 inhibits cell death in cellular models of Huntington's disease (HD), periventricular leukomalacia (PVL), and kidney dysfunction[2].
    Ferrostatin-1 (1 μM; 6 h) inhibits the oxidative destruction of unsaturated fatty acids in HT-1080 cells, thus increases the number of healthy medium spiny neurons (MSNs)[3].


    Ferroptosis-sensitive Cell Lines

    Ferroptosis-sensitive Cells Ferrostatin-1 Experimental Conditions Ferroptosis Inducers
    HT-1080[1] 0.5 μM; 24 h; EC50=60 nM Erastin (10 nM-100 μM; 24 h)
    BEAS-2B[4] 2 μM; 16 h LPS (10 mg/L; 16 h)
    PC12 (differentiated)[5] 1 μM; 12 h Erastin (7.5 μM; 12 h)
    N27 neuron[8] 0.004-0.25 μM; 24 h; EC50=0.039 μM RSL3 (1 μM; 24 h)
    BMSCs[9] 1 μM; 24 h GSDH (10-50 μM; 24 h)
    HT-22[10] 3-12 μM; 16 h Glutamate (5 mM; 16 h)
    HK‑2[11] 100 μM; 24 h Oxalate (2 mM; 24 h)
    MLE12[12] 1 and 5 μM; 24 h 8% and 20% cyclic stretching (CS)
    HaCaT[13] 10 μM UVB (20mJ/cm2)
    Mouse primary astrocytes[14] 0.1-2 μM; 24 h Angiotensin II (10 μM; 24 h)
    SKOV3[15] 5 μM; 24 h Erastin (10 μM; 24 h)
    OVCA429[15] 10 μM; 24 h Erastin (20 μM; 24 h)
    HK-2 WT[16] Pretreatment with 2 μM followed by co-treatment with inducers RSL3 (0.01-1 μM; 8 h)
    MDA-MB-468[16] Pretreatment with 2 μM for 1 h was performed, followed by co-treatment with the inducer RSL3 (500 nM; 2 h)
    NCI-H1299[16] Pretreatment with 2 μM followed by co-treatment with inducers Erastin (5 μM; 18 h)
    HT22 neuron[17] Cells were pretreated with the inducer and then co-treated with 10 and 20 μM Ferrostatin-1 for 6, 12, or 24 h Erastin (0 and 5 μM; 12 h)
    HT22 neuron[18] Pretreatment with 2 μM for 30 min was performed, followed by co-treatment with the inducer for 24 h Erastin (1 μM; 24 h)
    HT-1080[19] 0.5 μM; 12 h Erastin (10 μM; 12 h)
    H1975[20] Pretreatment with 2 μM for 14 h followed by co-treatment with the inducer for 24 h RSL3 (1 μM; 6 or 24 h)
    A549[20] Pretreatment with 2 μM for 14 h followed by co-treatment with the inducer for 24 h RSL3 (1 μM; 6 or 24 h)

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Ferrostatin-1 Related Antibodies
    In Vivo

    Ferrostatin-1 (5 mg/kg; ip; single dose, 30 min before glycerol injection) improves renal function in mice with rhabdomyolysis, whereas no beneficial effects were observed with the pan-caspase inhibitor zVAD or in RIPK3-deficient mice[1].
    Ferrostatin-1 (0.8 mg/kg; tail vein injection) effectively alleviates LPS-induced induced acute lung injury (ALI)[4].
    Ferrostatin-1 (i.p.; 5 mg/kg; C57BL/6J mice) improves renal function in mice with rhabdomyolysis[5].
    Ferrostatin-1 (10 mg/kg/d, i.p., 3 d) attenuates hypoxic-ischemic brain damage-, oxygen-glucose deprivation-, or Erastin (HY-15763)-induced ferroptosis in brain of neonatal rats[6].
    Ferrostatin-1 (0.655 mg/kg, i.p., 3 times a week for 6 week) exerts anti-ferroptosis effects by increasing GPX4 activity and by inhibiting lipid peroxidation in the salivary gland of ovariectomized (postmenopausal model) rats[7].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Male C57BL/6 mice (LPS-induced ALI)[4]
    Dosage: 0.8 mg/kg
    Administration: Tail vein injection
    Result: Exerted therapeutic action against LPS-induced ALI.
    Molecular Weight

    262.35

    Formula

    C15H22N2O2
    CAS No.

    347174-05-4
    Appearance

    Solid

    Color

    Gray to gray purple

    SMILES

    O=C(OCC)C1=CC=C(NC2CCCCC2)C(N)=C1
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    DMSO : 125 mg/mL (476.46 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.8117 mL 19.0585 mL 38.1170 mL
    5 mM 0.7623 mL 3.8117 mL 7.6234 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (7.93 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (7.93 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  50% PEG300    50% Saline

      Solubility: 5 mg/mL (19.06 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.96%

    SDS (393 KB)

    COA (245 KB) HNMR (269 KB) LCMS (267 KB) Elemental Analysis Report (104 KB)

    Handling Instructions (2659 KB)
    References

    • [1]. Dixon SJ, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060-1072.  [Content Brief]

      [2]. Skouta R, Dixon SJ, Wang J, et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc. 2014;136(12):4551-4556.  [Content Brief]

      [3]. Horwath MC, et al. Antifungal Activity of the Lipophilic Antioxidant Ferrostatin-1. Chembiochem. 2017;18(20):2069-2078.  [Content Brief]

      [4]. Liu P, Feng Y, et al. Ferrostatin-1 alleviates lipopolysaccharide-induced acute lung injury via inhibiting ferroptosis. Cell Mol Biol Lett. 2020;25:10. Published 2020 Feb 27.  [Content Brief]

      [5]. Melania Guerrero Hue, et al. FP282 FERROPTOSIS-MEDIATED CELL DEATH IS DECREASED BY CURCUMIN IN RENAL DAMAGE ASSOCIATED TO RHABDOMYOLYSIS, Nephrology Dialysis Transplantation, Volume 34, Issue Supplement_1, June 2019, gfz106.FP282.

      [6]. Zhang M, et al. Ferrostatin-1 attenuates hypoxic-ischemic brain damage in neonatal rats by inhibiting ferroptosis. Transl Pediatr. 2023 Nov 28;12(11):1944-1970.  [Content Brief]

      [7]. Cheon YI, et al. Effect of deferoxamine and ferrostatin-1 on salivary gland dysfunction in ovariectomized rats. Aging (Albany NY). 2023 Apr 6;15(7):2418-2432.  [Content Brief]

      [8]. Morrow J P, et al. Poly (2-oxazoline)–Ferrostatin-1 drug conjugates inhibit ferroptotic cell death[J]. Journal of Controlled Release, 2022, 350: 193-203.  [Content Brief]

      [9]. Xie Q, et al. Ferrostatin-1 improves BMSC survival by inhibiting ferroptosis[J]. Archives of Biochemistry and Biophysics, 2023, 736: 109535.  [Content Brief]

      [10]. Chu J, et al. Ferrostatin-1 protects HT-22 cells from oxidative toxicity[J]. Neural regeneration research, 2020, 15(3): 528-536.  [Content Brief]

      [11]. Xie J, et al. Ferrostatin‑1 alleviates oxalate‑induced renal tubular epithelial cell injury, fibrosis and calcium oxalate stone formation by inhibiting ferroptosis[J]. Molecular Medicine Reports, 2022, 26(2): 1-12.  [Content Brief]

      [12]. Ling M, et al. Ferrostatin-1 alleviates ventilator-induced lung injury by inhibiting ferroptosis[J]. International Immunopharmacology, 2023, 120: 110356.  [Content Brief]

      [13]. Li S, et al. Ferrostatin-1 alleviates angiotensin II (Ang II)-induced inflammation and ferroptosis in astrocytes[J]. International immunopharmacology, 2021, 90: 107179.  [Content Brief]

      [14]. Liu N, et al. Activation of the reverse transsulfuration pathway through NRF2/CBS confers erastin-induced ferroptosis resistance[J]. British journal of cancer, 2020, 122(2): 279-292.  [Content Brief]

      [15]. Zhang Z, et al. CGI1746 targets σ1R to modulate ferroptosis through mitochondria-associated membranes[J]. Nature Chemical Biology, 2024, 20(6): 699-709.  [Content Brief]

      [16]. Hanke N, et al. Inhibition of autophagy rescues HT22 hippocampal neurons from erastin-induced ferroptosis[J]. Neural regeneration research, 2023, 18(7): 1548-1552.  [Content Brief]

      [17]. Wang X, et al. Melatonin alleviates acute sleep deprivation-induced memory loss in mice by suppressing hippocampal ferroptosis[J]. Frontiers in pharmacology, 2021, 12: 708645.  [Content Brief]

      [18]. Du J, et al. Identification of Frataxin as a regulator of ferroptosis[J]. Redox biology, 2020, 32: 101483.  [Content Brief]

      [19]. Cheff D M, et al. The ferroptosis inducing compounds RSL3 and ML162 are not direct inhibitors of GPX4 but of TXNRD1[J]. Redox Biology, 2023, 62: 102703.  [Content Brief]

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.8117 mL 19.0585 mL 38.1170 mL 95.2925 mL
    5 mM 0.7623 mL 3.8117 mL 7.6234 mL 19.0585 mL
    10 mM 0.3812 mL 1.9059 mL 3.8117 mL 9.5293 mL
    15 mM 0.2541 mL 1.2706 mL 2.5411 mL 6.3528 mL
    20 mM 0.1906 mL 0.9529 mL 1.9059 mL 4.7646 mL
    25 mM 0.1525 mL 0.7623 mL 1.5247 mL 3.8117 mL
    30 mM 0.1271 mL 0.6353 mL 1.2706 mL 3.1764 mL
    40 mM 0.0953 mL 0.4765 mL 0.9529 mL 2.3823 mL
    50 mM 0.0762 mL 0.3812 mL 0.7623 mL 1.9059 mL
    60 mM 0.0635 mL 0.3176 mL 0.6353 mL 1.5882 mL
    80 mM 0.0476 mL 0.2382 mL 0.4765 mL 1.1912 mL
    100 mM 0.0381 mL 0.1906 mL 0.3812 mL 0.9529 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Ferrostatin-1 Related Classifications

    Help & FAQs

    Keywords:

    Ferrostatin-1347174-05-4Fer-1Ferrostatin1Ferrostatin 1Fer1Fer 1FerroptosisFungalantioxidantantifungalcelldeathcytosolicROSneurotoxicityInhibitorinhibitorinhibit

    You might also be interested by the following products:



    Cat#
    Description
    Cond.
    Price Bef. VAT
    8558-SC
    GSH/GSSG Ratio Assay
     100tests 
    8000-SC
    Umbilical Vein Endothelial Cells
     5x10^5cells/vial 
    1001-SC
    Endothelial Cell Medium
     500ml